Biopharmaceutical company Foresee Pharmaceuticals (TPEx:6576) announced on Sunday that it has successfully completed its Phase 1 single and multiple ascending dose clinical study in Australia for linvemastat (FP-020), a selective oral MMP-12 inhibitor.
The trial evaluated safety, tolerability, and pharmacokinetics in healthy subjects, with 40 participants in the single dose phase and 24 in the multiple dose phase.
Linvemastat is designed to treat inflammatory and fibrotic diseases, offering greater potency and selectivity than its predecessor, aderamastat (FP-025). Preclinical studies show favorable efficacy in respiratory and inflammatory bowel diseases. MMP-12, a key immune-fibrotic modulator, is linked to disease severity in asthma and COPD. Foresee plans to advance linvemastat for respiratory and fibrotic conditions.
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Shenzhen Chipscreen Biosciences' IND application for CS231295 tablets accepted in China
Sanofi and Orano partner to advance radioligand therapies
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
RaySearch secures RayStation orders from French cancer centers under Unicancer agreement
Merck's CAPVAXIVE shows promising immune responses in adults at risk of pneumococcal disease
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient